Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylbutazone-warfarin interaction in the dog.

K A Bachmann, A M Burkman

    The Journal of Pharmacy and Pharmacology
    |November 1, 1975
    PubMed
    Summary

    Phenylbutazone increases unbound warfarin in dogs, reducing its plasma half-life and enhancing its anticoagulant effect. This interaction highlights potential risks when co-administering these drugs in veterinary medicine.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [New guidelines on chronic pancreatitis : interdisciplinary treatment strategies].

    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2013
    Same author

    Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise.

    Current drug metabolism·2006
    Same author

    Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.

    Journal of clinical pharmacology·2001
    Same author

    The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions.

    Current drug metabolism·2001
    Same author

    Norastemizole Sepracor.

    Current opinion in investigational drugs (London, England : 2000)·2001
    Same author

    Differential kinetics of phenytoin in elderly patients.

    Drugs & aging·1999

    Area of Science:

    • Pharmacology
    • Veterinary Medicine
    • Drug Interactions

    Background:

    • Warfarin is an anticoagulant commonly used in veterinary medicine.
    • Phenylbutazone is a non-steroidal anti-inflammatory drug (NSAID) used in animals.
    • Drug interactions can alter the efficacy and safety of medications.

    Purpose of the Study:

    • To investigate the effect of phenylbutazone on warfarin's plasma protein binding and pharmacokinetics in dogs.
    • To evaluate the impact of this interaction on warfarin's anticoagulant activity.

    Main Methods:

    • Administration of phenylbutazone and warfarin to canine subjects.
    • Measurement of free and bound warfarin fractions in plasma.
    • Kinetic analysis of warfarin plasma half-life.
    • Assessment of hypoprothrombinaemia.

    Main Results:

    • Phenylbutazone significantly increased the free fraction of warfarin in plasma.
    • Warfarin's plasma half-life decreased by approximately 50% in phenylbutazone-treated dogs.
    • Co-administration led to marked increases in warfarin-induced hypoprothrombinaemia.

    Conclusions:

    • Phenylbutazone inhibits warfarin binding to plasma proteins in dogs.
    • This interaction accelerates warfarin elimination and potentiates its anticoagulant effect.
    • Caution is advised when co-administering phenylbutazone and warfarin in canine patients.

    Related Experiment Videos